KHG21834

has protective effect on amyloid beta-induced neurotoxicity in PC12 cells, cortical and mesencephalic neurons; structure in first source

Networked: 4 relevant articles (2 outcomes, 2 trials/studies)

1.	Neurodegenerative Diseases (Neurodegenerative Disease) 07/01/2010 - "These results, in combination with our previous findings on Abeta-induced degeneration, support the potential therapeutic efficacy of KHG21834 for the treatment of neurodegenerative disorders via the targeting of key glial activation pathways."
2.	Neuroinflammatory Diseases 06/01/2010 - "These results may suggest the potential therapeutic efficacy of KHG21834 for the treatment of ABeta-mediated neuroinflammation." 06/01/2010 - "In the present work, we show that KHG21834 reduces ABeta-mediated neuroinflammation in brain. " 06/01/2010 - "Attenuation of beta-amyloid-induced neuroinflammation by KHG21834 in vivo."
3.	Neuroblastoma 08/05/2019 - "The present study assessed the effects of the novel thiazole derivative KHG21834 against glutamate-induced toxicity in human neuroblastoma SH-SY5Y cell cultures. " 08/05/2019 - "KHG21834 attenuates glutamate-induced mitochondrial damage, apoptosis, and NLRP3 inflammasome activation in SH-SY5Y human neuroblastoma cells."
4.	Inflammation (Inflammations) 07/01/2010 - "In this study, we show that KHG21834 suppresses inflammation-mediated cytokine upregulation. "
5.	Pheochromocytoma 10/08/2007 - "We have investigated the effect of KHG21834, a benzothiazole derivative, on the amyloid beta protein (Abeta)-induced cell death in rat pheochromocytoma (PC12) cells and rat cortical and mesencephalic neuron-glia cultures. "